Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus LIPO GANTRISIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus LIPO GANTRISIN.
GANTRISIN vs LIPO GANTRISIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Lipo Gantrisin is a liposomal formulation of sulfisoxazole, a sulfonamide antibiotic. It inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby bacterial DNA replication.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
2-4 mL (80-160 mg sulfisoxazole equivalent) intramuscularly every 12 hours for 5-7 days.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
The terminal elimination half-life is approximately 7-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min). This necessitates dose adjustment in renal disease.
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Lipo Gantrisin is excreted primarily renally (70-80%) as unchanged drug and its acetylated metabolite. Biliary/fecal elimination accounts for 20-30%, with enterohepatic recirculation present.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic